Thyroid Cancer – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Thyroid Cancer – Pipeline Review, H1 2018’, provides an overview of the Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Thyroid Cancer

– The report reviews pipeline therapeutics for Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Thyroid Cancer therapeutics and enlists all their major and minor projects

– The report assesses Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Thyroid Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Advenchen Laboratories LLC

AstraZeneca Plc

Bayer AG

BeiGene Ltd

Biovista Inc

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Celldex Therapeutics Inc

Centrose LLC

CSPC Pharmaceutical Group Limited

Curis Inc

CytImmune Sciences Inc

Cytori Therapeutics Inc

Ecrins Therapeutics SAS

Eisai Co Ltd

Ensol Biosciences Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Genelux Corp

Genmab A/S

GlaxoSmithKline Plc

Gradalis Inc

Hutchison MediPharma Ltd

Ignyta Inc

Immunomedics Inc

Johnson & Johnson

Konruns Pharmaceutical Co Ltd

Loxo Oncology Inc

MacroGenics Inc

MaxiVAX SA

MedImmune LLC

Merck & Co Inc

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Nerviano Medical Sciences Srl

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

Plexxikon Inc

Rodos BioTarget GmbH

Sino Biopharmaceutical Ltd

Synactix Pharmaceuticals Inc

Tarveda Therapeutics Inc

Vaccinex Inc

Vascular Biogenics Ltd

Xspray Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Thyroid Cancer Overview 6

Thyroid Cancer Therapeutics Development 7

Thyroid Cancer Therapeutics Assessment 21

Thyroid Cancer Companies Involved in Therapeutics Development 35

Thyroid Cancer Drug Profiles 58

Thyroid Cancer Dormant Projects 541

Thyroid Cancer Discontinued Products 543

Thyroid Cancer Product Development Milestones 544

Appendix 556

List of Tables

List of Tables

Number of Products under Development for Thyroid Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Thyroid Cancer Pipeline by AbbVie Inc, H1 2018

Thyroid Cancer Pipeline by Advenchen Laboratories LLC, H1 2018

Thyroid Cancer Pipeline by AstraZeneca Plc, H1 2018

Thyroid Cancer Pipeline by Bayer AG, H1 2018

Thyroid Cancer Pipeline by BeiGene Ltd, H1 2018

Thyroid Cancer Pipeline by Biovista Inc, H1 2018

Thyroid Cancer Pipeline by Blueprint Medicines Corp, H1 2018

Thyroid Cancer Pipeline by Boehringer Ingelheim GmbH, H1 2018

Thyroid Cancer Pipeline by Bristol-Myers Squibb Co, H1 2018

Thyroid Cancer Pipeline by Celgene Corp, H1 2018

Thyroid Cancer Pipeline by Celldex Therapeutics Inc, H1 2018

Thyroid Cancer Pipeline by Centrose LLC, H1 2018

Thyroid Cancer Pipeline by CSPC Pharmaceutical Group Limited, H1 2018

Thyroid Cancer Pipeline by Curis Inc, H1 2018

Thyroid Cancer Pipeline by CytImmune Sciences Inc, H1 2018

Thyroid Cancer Pipeline by Cytori Therapeutics Inc, H1 2018

Thyroid Cancer Pipeline by Ecrins Therapeutics SAS, H1 2018

Thyroid Cancer Pipeline by Eisai Co Ltd, H1 2018

Thyroid Cancer Pipeline by Ensol Biosciences Inc, H1 2018

Thyroid Cancer Pipeline by Exelixis Inc, H1 2018

Thyroid Cancer Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Thyroid Cancer Pipeline by Genelux Corp, H1 2018

Thyroid Cancer Pipeline by Genmab A/S, H1 2018

Thyroid Cancer Pipeline by GlaxoSmithKline Plc, H1 2018

Thyroid Cancer Pipeline by Gradalis Inc, H1 2018

Thyroid Cancer Pipeline by Hutchison MediPharma Ltd, H1 2018

Thyroid Cancer Pipeline by Ignyta Inc, H1 2018

Thyroid Cancer Pipeline by Immunomedics Inc, H1 2018

Thyroid Cancer Pipeline by Johnson & Johnson, H1 2018

Thyroid Cancer Pipeline by Konruns Pharmaceutical Co Ltd, H1 2018

Thyroid Cancer Pipeline by Loxo Oncology Inc, H1 2018

Thyroid Cancer Pipeline by MacroGenics Inc, H1 2018

Thyroid Cancer Pipeline by MaxiVAX SA, H1 2018

Thyroid Cancer Pipeline by MedImmune LLC, H1 2018

Thyroid Cancer Pipeline by Merck & Co Inc, H1 2018

Thyroid Cancer Pipeline by Mersana Therapeutics Inc, H1 2018

Thyroid Cancer Pipeline by Millennium Pharmaceuticals Inc, H1 2018

Thyroid Cancer Pipeline by Nerviano Medical Sciences Srl, H1 2018

Thyroid Cancer Pipeline by Novartis AG, H1 2018

Thyroid Cancer Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Thyroid Cancer Pipeline by Pfizer Inc, H1 2018

Thyroid Cancer Pipeline by Plexxikon Inc, H1 2018

Thyroid Cancer Pipeline by Rodos BioTarget GmbH, H1 2018

Thyroid Cancer Pipeline by Sino Biopharmaceutical Ltd, H1 2018

Thyroid Cancer Pipeline by Synactix Pharmaceuticals Inc, H1 2018

Thyroid Cancer Pipeline by Tarveda Therapeutics Inc, H1 2018

Thyroid Cancer Pipeline by Vaccinex Inc, H1 2018

Thyroid Cancer Pipeline by Vascular Biogenics Ltd, H1 2018

Thyroid Cancer Pipeline by Xspray Pharma AB, H1 2018

Thyroid Cancer Dormant Projects, H1 2018

Thyroid Cancer Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Thyroid Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports